教室紹介

2022年業績集

受賞

  1. 第9回泌尿器画像診断・治療技術研究会 ベストポスターアワード 優秀賞
    藤原 基裕、吉田 宗一郎、高原 太郎、吉富 香澄、相馬 貴彦、小林 正貴、中村 祐基、范 博、石川 雄大、福田 翔平、早稲田 悠馬、上原 翔、田中 一、横山 みなと、藤井 靖久. 第9回泌尿器画像診断・治療技術研究会(JSURT) 2022年8月6日

原著

  1. Nishizawa M, Kudo T, Kijima T, Fujii Y. Failed endovascular abdominal aortic aneurysm repair due to Mycobacterium bovis infection following intravesical bacillus Calmette-Gu ́erin therapy. J Vasc Surg Cases Innov Tech. 8(4); 807-812, 2022. PubMed

  2. Yuan JH, Tanaka H, Patil D, Hakimi K, Soliman S, Meagher MF, Saidian A, Walia A, Dhanji S, Liu F, Afari J, Nguyen M, Wang L, Yasuda Y, Saito K, Fujii Y, Master V, Derweesh IH. Age-Related Differences in Oncological Outcomes in Renal Cell Carcinoma: Impact of Functional Conservation as Measured by Postoperative eGFR. Clin Genitourin Cancer. S1558-7673, 2022. PubMed

  3. Nakamura Y, Fukushima H, Yoshitomi K, Soma T, Kobayashi M, Fan B, Fujiwara M, Ishikawa Y, Fukuda S, Waseda Y, Tanaka H, Yoshida S, Yokoyama M, Fujii Y. Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer. Int J Urol. 30(4); 381-388, 2022.PubMed

  4. Yamaguchi Y, Yokoyama M, Takemoto A, Nakamura Y, Fukuda S, Uehara S, Tanaka H, Yoshida S, Matsuoka Y, Fujii Y. Succinate dehydrogenase-deficient malignant paraganglioma complicated by succinate dehydrogenase-deficient renal cell carcinoma. IJU case reports. 5(6); 480-483, 2022.PubMed

  5. Fukagawa E, Yuasa T, Inamura K, Hamada K, Fujiwara M, Komai Y, Yonese J. De novo large-cell neuroendocrine carcinoma of the prostate: A case report and literature review. IJU Case Rep. 5(6); 505-510, 2022.PubMed

  6. Yonese I, Ito M, Waseda Y, Kobayashi S, Toide M, Takazawa R, Koga F. Adverse Prognostic Impact of Diagnostic Ureterorenoscopy in a Subset of Patients with High-Risk Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. Cancers. 14(16); 3962, 2022.PubMed

  7. Yamamoto S, Fukushima H, Fukuda S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Fujii Y. Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab. Asia Pac J Clin Oncol. 18(4); 410-418, 2022.PubMed

  8. Tanaka H, Fujii Y. Editorial Comment to Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma Int J Urol. 29(8); 822-823, 2022.PubMed

  9. Miyauchi M, Akashi T, Furukawa A, Uchida K, Tamura T, Ando N, Kirimura S, Shintaku H, Yamamoto K, Ito T, Miura K, Kayamori K, Ariizumi Y, Asakage T, Kudo A, Tanabe M, Fujii Y, Ishibashi H, Okubo K, Murakami M, Yamada T, Takemoto A, Bae Y, Eishi Y, Ohashi K. Endocr Pathol. PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma Endocr Pathol. 33(4); 506-518, 2022.PubMed

  10. Toide M, Saito K, Yasuda Y, Tanaka H, Fukuda S, Patil D, Cotta BH, Patel SH, Master VA, Derweesh IH, Fujii Y. Prognostic Significance of C-reactive Protein in Patients with Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort. Clin Genitourin Cancer. 20(4); 276-282, 2022.PubMed

  11. Waseda Y, Takazawa R, Kobayashi M, Fuse H, Tamiya T. Different failure rates of insertion of 10/12-Fr ureteral access sheaths during retrograde intrarenal surgery in patients with and without stones. Investig Clin Urol. 63(4); 433-440, 2022.PubMed

  12. Waseda Y, Takazawa R, Kobayashi M, Fuse H, Tamiya T. Risk factors and predictive model for incidence of difficult ureter during retrograde ureteroscopic lithotripsy. Int J Urol. 29(6); 542-546, 2022.PubMed

  13. Waseda Y, Takazawa R. Re: Editorial Comment to Risk factors and predictive model for incidence of difficult ureter during retrograde ureteroscopic lithotripsy. Int J Urol. 29(6); 547, 2022.PubMed

  14. Matsumoto S, Arita Y, Yoshida S, Fukushima H, Kimura K, Yamada I, Tanaka H, Yagi F, Yokoyama M, Matsuoka Y, Oya M, Tateishi U, Jinzaki M, Fujii Y. Utility of radiomics features of diffusion-weighted magnetic resonance imaging for differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma: model development and external validation. Abdom Radiol. 47(6); 2178-2186, 2022.PubMed

  15. Tanaka H, Fujii Y. Editorial Comment to Surgical and focal treatment for metastatic renal cell carcinoma: A literature review. Int J Urol. 29(6); 501-502, 2022.PubMed

  16. Yoshitomi KK, Komai Y, Yamamoto T, Fukagawa E, Hamada K, Yoneoka Y, Fujiwara M, Fujiwara R, Oguchi T, Numao N, Yuasa T, Yamamoto S, Fukui I, Yonese J. Improving Accuracy, Reliability, and Efficiency of the RENAL Nephrometry Score With 3D Reconstructed Virtual Imaging. Urology. 164; 286-292, 2022.PubMed

  17. Fujiwara M, Numao N, Yamamoto S, Ishikawa Y, Fujiwara R, Oguchi T, Komai Y, Matsuoka Y, Yuasa T, Yonese J. Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side-specific negative lymph node metastasis at radical prostatectomy. Prostate. 82(8); 904-910, 2022.PubMed

  18. Meagher MF, Patil D, Saito K, Javier-Desloges JF, Bradshaw AW, Patel SH, Cotta BH, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh IH. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans with Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology. 163; 164-176, 2022.PubMed

  19. Matsuoka Y, Uehara S, Toda K, Fukushima H, Tanaka H, Yoshida S, Yokoyama M, Yoshimura R, Kihara K, Fujii Y. Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy. Urol Oncol. 40(4); 161, 2022.PubMed

  20. Rathi N, Palacios DA, Abramczyk E, Tanaka H, Ye Y, Li J, Yasuda Y, Abouassaly R, Eltemamy M, Wee A, Weight C, Campbell SC. Predicting GFR after radical nephrectomy: the importance of split renal function. World J Urol. 40(4); 1011-1018, 2022.PubMed

  21. Fujiwara M, Fujiwara R, Urasaki T, Oguchi T, Komai Y, Numao N, Yamamoto S, Yonese J, Yuasa T. Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer. Anticancer Res. 42(4); 2045-2051, 2022.PubMed

  22. Fujiwara M, Fujiwara R, Oguchi T, Komai Y, Numao N, Yamamoto S, Yonese J, Yuasa T. Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy. Anticancer Res. 42(4); 2123-2130, 2022.PubMed

  23. Arita Y, Yoshida S, Kwee TC, Edo H, Kufukihara R, Shigeta K, Nagasaka M, Takeshita R, Okamura H, Ueda R, Ishii R, Okuda S, Fujii Y. Clinical utility of the Bosniak classification version 2019: Diagnostic value of adding magnetic resonance imaging to computed tomography examination. Eur J Radiol. 148; 110163, 2022.PubMed

  24. Arita Y, Akita H, Fujiwara H, Hashimoto M, Shigeta K, Kwee TC, Yoshida S, Kosaka T, Okuda S, Oya M, Jinzaki M. Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements. Eur J Radiol Open. 15(9); 100403, 2022.PubMed

  25. Yoshida S, Fujii Y. Editorial Comment from Dr Yoshida and Dr Fujii to Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis. Int J Urol. 29(3); 196, 2022.PubMed

  26. Yoshida S, Matsushima H, Fujii Y. Classification of oligometastatic prostate cancer with additional consideration for hormone sensitivity. World J Urol . 40(3); 871-873, 2022.PubMed

  27. Uchida Y, Yoshida S, Arita Y, Shimoda H, Kimura K, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Jinzaki M, Fujii Y. Apparent Diffusion Coefficient Map-Based Texture Analysis for the Differentiation of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma. Diagnostics. 12(4); 817, 2022.PubMed

  28. Yoshida S, Takahara T, Arita Y, Toda K, Kimura K, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Fujii Y. Impact of Progressive Site-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer on Subsequent Treatment Response. Cancer. 14(3); 567, 2022.PubMed

  29. Kobayashi M, Waseda Y, Fuse H, Takazawa R. Variables measured on three-dimensional computed tomography are preferred for predicting the outcomes of shock wave lithotripsy. World journal of urology. 40(2); 569-575, 2022.PubMed

  30. Kimura K, Yoshida S, Tsuchiya J, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Tateishi U, Fujii Y. Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer. Eur Radiol. 32(1); 671-679, 2022.PubMed

  31. Keiner C, Meagher M, Patil D, Saito K, Walia A, Liu F, Dutt R, Miller N, Dhanji S, Saidian A, Wan F, Yasuda Y, Fujii Y, Tanaka H, Master V, Derweesh I. Association of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and De Ritis ratio with mortality in renal cell carcinoma: A multicenter analysis. Front Oncol. 12; 995991, 2022.PubMed

  32. Preedanan W, Suzuki K, Kondo T, Kobayashi M, Tanaka H, Ishioka J, Matsuoka Y, Fujii Y, Kumazawa I. Improvement of Urinary Stone Segmentation Using GAN-Based Urinary Stones Inpainting Augmentation. IEEE Access. 10; 115131-115142, 2022.doi

  33. Rossi SH, Tanaka H, Usher-Smith JA, Bernhard JC, Fujii Y, Stewart GD. Kidney Cancer Screening and Epidemiology. Soci ́et ́e Internationale d'Urologie Journal. 3(6); 2022.doi

  34. Uchida Y, Yokoyama M, Nakamura Y, Fukuda S, Uehara S, Tanaka H, Yoshida S, Matsuoka Y, Fujii Y. Assessment of erectile and ejaculatory functions after bladder-sparing therapy against muscle-invasive bladder cancer. J Sex Med. 19(5); S196-197, 2022. doi

  35. Yoshida S, Takahara T, Arita Y, Toda K, Kimura K, Fujiwara M, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Fujii Y. Patterns of recurrence in genuine and induced oligometastatic castration-resistant prostate cancer treated with progressive site-directed therapy. Int J Urol. 30(2); 204-210, 2023.PubMed

  36. Arita Y, Yoshida S, Shigeta K, Kwee TC, Edo H, Okawara N, Hashimoto M, Ishii R, Ueda R, Mikami S, Fujiwara M, Waseda Y, Kikuchi E, Fujii YJinzaki M. Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology. Eur Urol Oncol. 6(1); 99-102, 2023. PubMed

  37. Arita Y, Yoshida S, Shigeta K, Kwee TC, Edo H, Okawara N, Hashimoto M, Ishii R, Ueda R, Mikami S, Fujiwara M, Waseda Y, Kikuchi E, Fujii Y, Jinzaki M. Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology. Eur Urol Oncol. 6(1); 99-102, 2023. PubMed

  38. Fujiwara R, Yuasa T, Yamamoto S, Fujiwara M, Takemura K, Urasaki T, Oki R, Komai Y, Oguchi T, Numao N, Yonese J. Geriatric Nutritional Risk Index as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated with Nivolumab. Nutr Cancer. 75(2); 670-677, 2023. PubMed

  39. Chen W, Yokoyama M, Kobayashi M, Fan B, Fukuda S, Waseda Y, Tanaka H, Yoshida S, Ai M, Fushimi K, Nonomura N, Fujii Y. Trends of radical cystectomy and comparisons of surgical outcomes among surgical approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide database study. Int J Urol. 30(3); 258-263, 2023.PubMed

  40. Nguyen MV, Walia A, Saidian A, Puri D, Meagher MF, Hakimi K, Tanaka H, Patil D, Yasuda Y, Saito K, Dhanji S, Cerrato C, Narasimhan R, Perry J, Master V, Fujii Y, Derweesh IH. Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD-na ̈ıve patients on survival in renal cell carcinoma. BJU Int. 131(2); 219-226, 2023.PubMed